A combination treatment with recombinant human vascular endothelial growth factor C and eNOS inhibitor (Nω‐nitro‐l‐arginine methyl ester hydrochloride) resulted in the down‐regulation of p‐VASP, as well as a decreased migration and invasion ability of the CCA cell line. Here, VEGFC is linked to cholangiocarcinoma.